Results of a Single-Center Experience With Resection and Ablation for Sarcoma Metastatic to the Liver

LAUR Repository

Show simple item record

dc.contributor.author Abdalla, Eddie
dc.contributor.author Pawlik, Timothy
dc.contributor.author Vauthey, Nicolas
dc.contributor.author Pollock, Raphael
dc.contributor.author Ellis, Lee
dc.contributor.author Curley, Steven
dc.date.accessioned 2015-11-12T09:51:19Z
dc.date.available 2015-11-12T09:51:19Z
dc.date.copyright 2006
dc.date.issued 2015-11-12
dc.identifier.issn 2168-6254 en_US
dc.identifier.uri http://hdl.handle.net/10725/2545
dc.description.abstract Hypothesis A subset of patients with sarcoma liver metastasis may benefit from hepatic resection and/or ablation. Design Retrospective review of prospectively collected cancer center database records. Patients and Methods Sixty-six patients who underwent hepatic resection and/or open radiofrequency ablation of metastatic sarcoma between July 1, 1996, and April 30, 2005, were identified from the database. Clinicopathologic, operative, recurrence, and long-term survival data were analyzed. Results The primary sarcoma site was the abdomen or retroperitoneum (n = 22), stomach (n = 18), small or large bowel (n = 17), pelvis (n = 4), uterus (n = 3), or other (n = 2). Tumor pathologic types included gastrointestinal stromal tumor (n = 36), leiomyosarcoma (n = 18), and sarcoma not otherwise classified (n = 12). Thirty-five patients underwent resection, 18 underwent resection plus radiofrequency ablation, and 13 underwent radiofrequency ablation only. With a median follow-up of 35.8 months, 44 patients (66.7%) had recurrence (intrahepatic only, n = 16; extrahepatic only, n = 11; both, n = 17). Treatment with radiofrequency ablation (either alone or combined with resection) (P = .002) and lack of adjuvant chemotherapy (P = .01) predicted shorter disease-free survival. The 1-, 3-, and 5-year overall survival rates were 91.2%, 65.4%, and 27.1%, respectively. Patients with gastrointestinal stromal tumor who were treated with adjuvant imatinib mesylate had the longest median survival (not reached) (P = .003). Conclusions Long-term survival can be achieved following surgical treatment of sarcoma liver metastasis, especially in patients with gastrointestinal stromal tumor. Patients with sarcoma liver metastasis should be evaluated by a multidisciplinary team, as recurrence is common and adjuvant therapy may prolong survival. en_US
dc.language.iso en en_US
dc.title Results of a Single-Center Experience With Resection and Ablation for Sarcoma Metastatic to the Liver en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201100945 en_US
dc.author.woa N/A en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal JAMA Surgery en_US
dc.journal.volume 141 en_US
dc.journal.issue 6 en_US
dc.article.pages 537-544 en_US
dc.identifier.doi http://dx.doi.org/10.1001/archsurg.141.6.537 en_US
dc.identifier.ctation Pawlik, T. M., Vauthey, J. N., Abdalla, E. K., Pollock, R. E., Ellis, L. M., & Curley, S. A. (2006). Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Archives of surgery, 141(6), 537-544. en_US
dc.author.email eddie.abdalla@lau.edu.lb
dc.identifier.url http://archsurg.jamanetwork.com/article.aspx?articleid=398557

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account